AstraZeneca and Pozen have submitted a marketing authorization application or MAA in the EU via the decentralized procedure for Vimovo tablets, a product under investigation for the treatment of the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who are at risk of developing non-steroidal anti-inflammatory drug-associated ulcers. Vimovo is a fixed-dose combination of enteric coated naproxen and immediate release esomeprazole under co-development by AstraZeneca and Pozen.

For  the full story, Click Here